SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddy's Lab faces Betapharm writedowns

24 Feb 2009 Evaluate

Hyderabad-based Dr Reddy's Laboratories (DRL) may have to write down the intangible value of major products in its German subsidiary Betapharm during the current quarter, which may squeeze the Indian firm's earnings for FY09.

 

DRL has already made two major provisions towards Betapharm impairments of over Rs 400 crore. However, the spokesman did not confirm the exact quantum of the provisions made so far.

 

The unimpaired goodwill in respect of the major products marketed by Betapharm is currently estimated at about 150 million euros. Thus the provision for impairments and pricing pressure in the German market are likely to impact the earnings of the company in the current financial year.

crackcrack

Dr. Reddys Lab Share Price

1232.00 19.65 (1.62%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×